Blog

PNI’s Year-in-Review 2020 was, despite the pandemic, a strong year for clinical care delivered by PNI providers with multiple milestones being achieved.  We’ve entered 2021 with a deep commitment to treating our patients at our ten centers of excellence, doing groundbreaking research, providing innovative clinical...

The Think Neuro podcast from Pacific Neuroscience Institute takes you into the clinic, operating room and laboratory with doctors and surgeons who are tackling the most challenging brain diseases and disorders. Host: Anthony Effinger Subscribe: Google Podcasts | Apple Podcasts | Spotify | Simplecast Watch: YouTube Episode 12: Show Notes One in ten Americans...

Although our medical community continues to strain under the burden of COVID-19, there has been hope, determination and progress. Neurological diseases do not stop and neither have we at Pacific Neuroscience Institute.

New Studies Blue Earth Diagnostics FLC-219: (PDF): An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases After Radiation Therapy (PURSUE) (NCT04410367) Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience (PDF): A...

Alzheimer’s disease is a neurodegenerative condition that affects thinking, behavior and social skills. Dr. Verna Porter, Director of the Dementia, Alzheimer’s Disease and Neurocognitive Disorders Program at Pacific Brain Health Center, talked about some everyday questions that people have with regard to this disease. 1....

Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience (PDF): A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma (NCT03463265) Orbus Therapeutics (PDF): A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine...

Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience (PDF): A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma (NCT03463265) Orbus Therapeutics (PDF): A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine...

Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience ( PDF ): A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma ( NCT03463265 ) Orbus Therapeutics ( PDF ): A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine...

Will & Cary Singleton Donate $40 Million to Pacific Neuroscience Institute’s Brain Health Center for Alzheimer’s Treatment & Research SANTA MONICA (July 7, 2020) –A $40 million donation from Will and Cary Singleton will support the Pacific Neuroscience Institute (PNI) Brain Health Center at Providence...

U.S. News & World Report highlights quality, specialty care Ten Providence Southern California hospitals and affiliated partners in Los Angeles and Orange counties earned recognition on July 28, 2020, from U.S. News & World Report. With approximately 415 acute care hospitals in California, the 10...